CTLA4 and melanoma: Some phase I and II trials showed disease stabilization in various malignancies, and the phase Ib trial (NCT03293784) combining TNF inhibitor certolizumab with anti-PD-1/anti-CTLA-4 in melanoma patients demonstrated safety and high response rates (58, 102).